🇺🇸 FDA
Patent

US 11801296

Development of a novel live attenuated African swine fever vaccine based in the deletion of gene A137R

granted A61KA61K2039/5254A61K2039/552

Quick answer

US patent 11801296 (Development of a novel live attenuated African swine fever vaccine based in the deletion of gene A137R) held by The United States of America, as represented by the Secretary of Agriculture expires Mon Oct 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary of Agriculture
Grant date
Tue Oct 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K2039/5254, A61K2039/552, A61K39/12, A61P